Singular Genomics Valuation
| OMIC Stock | USD 21.90 0.09 0.41% |
At this time, the company appears to be overvalued. Singular Genomics Systems has a current Real Value of $9.26 per share. The regular price of the company is $21.9. Our model measures the value of Singular Genomics Systems from inspecting the company fundamentals such as Current Valuation of (8.57 M), shares owned by insiders of 13.90 %, and Return On Equity of -0.52 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Singular Genomics' valuation include:
Price Book 0.4444 | Enterprise Value -8.6 M | Enterprise Value Ebitda 0.7749 | Price Sales 20.1136 |
Overvalued
Today
Please note that Singular Genomics' price fluctuation is very risky at this time. Calculation of the real value of Singular Genomics Systems is based on 3 months time horizon. Increasing Singular Genomics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Singular Genomics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Singular Stock. However, Singular Genomics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 21.9 | Real 9.26 | Target 0.7 | Hype 20.44 | Naive 18.19 |
The real value of Singular Stock, also known as its intrinsic value, is the underlying worth of Singular Genomics Systems Company, which is reflected in its stock price. It is based on Singular Genomics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Singular Genomics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Singular Genomics Systems helps investors to forecast how Singular stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Singular Genomics more accurately as focusing exclusively on Singular Genomics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Singular Genomics' intrinsic value based on its ongoing forecasts of Singular Genomics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Singular Genomics' closest peers. If more than one evaluation category is relevant for Singular Genomics we suggest using both methods to arrive at a better estimate.
Singular Genomics Cash |
|
Singular Valuation Trend
Comparing Singular Genomics' enterprise value against its market capitalization is a good way to estimate the value of Singular Genomics Systems uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Singular Revenue by Product
Singular Genomics Total Value Analysis
Singular Genomics Systems is now forecasted to have valuation of (8.57 M) with market capitalization of 54.77 M, debt of 75.29 M, and cash on hands of 287.98 M. The negative valuation of Singular Genomics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Singular Genomics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(8.57 M) | 54.77 M | 75.29 M | 287.98 M |
Singular Genomics Investor Information
About 14.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.44. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Singular Genomics Systems recorded a loss per share of 34.68. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 26th of June 2024. Based on the key indicators related to Singular Genomics' liquidity, profitability, solvency, and operating efficiency, Singular Genomics Systems is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Singular Genomics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Singular Genomics has an asset utilization ratio of 1.1 percent. This indicates that the Company is making $0.011 for each dollar of assets. An increasing asset utilization means that Singular Genomics Systems is more efficient with each dollar of assets it utilizes for everyday operations.Singular Genomics Ownership Allocation
The market capitalization of Singular Genomics is $54.77 Million. Over half of Singular Genomics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.Singular Genomics Profitability Analysis
The company reported the previous year's revenue of 2.91 M. Net Loss for the year was (94.82 M) with loss before overhead, payroll, taxes, and interest of (24 K).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Singular Genomics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Singular Genomics and how it compares across the competition.
About Singular Genomics Valuation
The stock valuation mechanism determines Singular Genomics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Singular Genomics. We calculate exposure to Singular Genomics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Singular Genomics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -558 K | -585.9 K | |
| Pretax Profit Margin | (32.57) | (34.20) | |
| Operating Profit Margin | (35.31) | (37.08) | |
| Net Loss | (32.57) | (34.20) | |
| Gross Profit Margin | (0.19) | (0.20) |
Singular Genomics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 2.4 M |
Singular Genomics Current Valuation Indicators
Valuation refers to the process of determining the present value of Singular Genomics Systems and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Singular we look at many different elements of the entity such as Singular's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Singular Genomics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Singular Genomics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Singular Genomics' worth.Complementary Tools for Singular Stock analysis
When running Singular Genomics' price analysis, check to measure Singular Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Singular Genomics is operating at the current time. Most of Singular Genomics' value examination focuses on studying past and present price action to predict the probability of Singular Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Singular Genomics' price. Additionally, you may evaluate how the addition of Singular Genomics to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |